Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Donnelley Financial Solutions, Inc. stock logo
DFIN
Donnelley Financial Solutions
$45.07
+0.6%
$44.90
$37.80
$71.01
$1.29B1.23219,149 shs361,319 shs
Ibotta, Inc. stock logo
IBTA
Ibotta
$48.36
-0.2%
$45.60
$31.40
$110.63
$1.28BN/A439,091 shs231,123 shs
MultiPlan Co. stock logo
MPLN
MultiPlan
$22.57
+1.6%
$21.24
$4.80
$31.01
$364.98M0.13113,616 shs71,787 shs
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
$10.27
+1.8%
$9.84
$8.05
$19.12
$1.32B1.41965,663 shs1.43 million shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Donnelley Financial Solutions, Inc. stock logo
DFIN
Donnelley Financial Solutions
+3.55%+6.96%-1.95%-33.22%-31.13%
Ibotta, Inc. stock logo
IBTA
Ibotta
+4.30%+1.87%+14.70%-34.97%+4,852,999,900.00%
MultiPlan Co. stock logo
MPLN
MultiPlan
+8.71%+9.35%+4.56%+37.75%+2,221,999,900.00%
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
+1.82%+5.65%+1.31%-32.10%-28.08%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Donnelley Financial Solutions, Inc. stock logo
DFIN
Donnelley Financial Solutions
3.5745 of 5 stars
3.54.00.00.02.24.21.3
Ibotta, Inc. stock logo
IBTA
Ibotta
0.5118 of 5 stars
1.51.00.80.02.30.80.0
MultiPlan Co. stock logo
MPLN
MultiPlan
0.9342 of 5 stars
2.00.00.00.02.21.70.6
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
2.6379 of 5 stars
3.43.00.00.03.31.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Donnelley Financial Solutions, Inc. stock logo
DFIN
Donnelley Financial Solutions
3.00
Buy$71.3358.27% Upside
Ibotta, Inc. stock logo
IBTA
Ibotta
3.00
Buy$50.003.39% Upside
MultiPlan Co. stock logo
MPLN
MultiPlan
2.00
Hold$26.2516.30% Upside
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
2.80
Moderate Buy$19.3087.93% Upside

Current Analyst Ratings Breakdown

Latest MPLN, NEO, IBTA, and DFIN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/17/2025
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$17.00 ➝ $15.00
4/14/2025
Donnelley Financial Solutions, Inc. stock logo
DFIN
Donnelley Financial Solutions
DA Davidson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$72.00 ➝ $72.00
4/14/2025
Ibotta, Inc. stock logo
IBTA
Ibotta
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$56.00 ➝ $50.00
3/28/2025
Donnelley Financial Solutions, Inc. stock logo
DFIN
Donnelley Financial Solutions
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$72.00 ➝ $72.00
2/26/2025
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$21.00 ➝ $18.00
2/20/2025
Donnelley Financial Solutions, Inc. stock logo
DFIN
Donnelley Financial Solutions
DA Davidson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$76.00 ➝ $72.00
2/19/2025
Donnelley Financial Solutions, Inc. stock logo
DFIN
Donnelley Financial Solutions
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$79.00 ➝ $72.00
2/19/2025
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$19.00 ➝ $16.00
2/19/2025
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$19.00 ➝ $18.00
1/28/2025
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$20.00 ➝ $18.00
(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Donnelley Financial Solutions, Inc. stock logo
DFIN
Donnelley Financial Solutions
$781.90M1.64$4.98 per share9.05$15.24 per share2.96
Ibotta, Inc. stock logo
IBTA
Ibotta
$367.25M3.47N/AN/AN/A
MultiPlan Co. stock logo
MPLN
MultiPlan
$930.62M0.39$13.76 per share1.64$105.45 per share0.21
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
$660.57M2.00$0.38 per share27.03$7.02 per share1.46
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Donnelley Financial Solutions, Inc. stock logo
DFIN
Donnelley Financial Solutions
$82.20M$3.0614.73N/A11.82%20.65%10.41%4/30/2025 (Estimated)
Ibotta, Inc. stock logo
IBTA
Ibotta
N/A$1.7927.02N/AN/AN/AN/AN/A
MultiPlan Co. stock logo
MPLN
MultiPlan
-$91.70M-$101.54N/AN/AN/A-163.30%-12.14%-1.84%5/6/2025 (Estimated)
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
-$87.97M-$0.62N/A114.11N/A-11.92%-2.10%-1.17%4/29/2025 (Estimated)

Latest MPLN, NEO, IBTA, and DFIN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2025Q1 2025
MultiPlan Co. stock logo
MPLN
MultiPlan
-$2.14N/AN/AN/AN/AN/A
4/30/2025Q1 2025
Donnelley Financial Solutions, Inc. stock logo
DFIN
Donnelley Financial Solutions
$0.7330N/AN/AN/A$194.47 millionN/A
4/29/2025Q1 2025
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
-$0.02N/AN/AN/A$171.38 millionN/A
2/18/2025Q4 2024
Donnelley Financial Solutions, Inc. stock logo
DFIN
Donnelley Financial Solutions
$0.48$0.26-$0.22$0.21$169.20 million$156.30 million
2/18/2025Q4 2024
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
$0.03-$0.02-$0.05-$0.12$173.40 million$172.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Donnelley Financial Solutions, Inc. stock logo
DFIN
Donnelley Financial Solutions
N/AN/AN/AN/AN/A
Ibotta, Inc. stock logo
IBTA
Ibotta
$0.020.04%N/A1.12%N/A
MultiPlan Co. stock logo
MPLN
MultiPlan
N/AN/AN/AN/AN/A
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Donnelley Financial Solutions, Inc. stock logo
DFIN
Donnelley Financial Solutions
0.29
1.04
1.15
Ibotta, Inc. stock logo
IBTA
Ibotta
N/AN/AN/A
MultiPlan Co. stock logo
MPLN
MultiPlan
21.73
1.05
1.05
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
0.38
1.98
1.91

Institutional Ownership

CompanyInstitutional Ownership
Donnelley Financial Solutions, Inc. stock logo
DFIN
Donnelley Financial Solutions
93.84%
Ibotta, Inc. stock logo
IBTA
Ibotta
N/A
MultiPlan Co. stock logo
MPLN
MultiPlan
87.15%
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
98.50%

Insider Ownership

CompanyInsider Ownership
Donnelley Financial Solutions, Inc. stock logo
DFIN
Donnelley Financial Solutions
11.90%
Ibotta, Inc. stock logo
IBTA
Ibotta
16.08%
MultiPlan Co. stock logo
MPLN
MultiPlan
8.00%
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
1.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Donnelley Financial Solutions, Inc. stock logo
DFIN
Donnelley Financial Solutions
2,15028.53 million25.21 millionOptionable
Ibotta, Inc. stock logo
IBTA
Ibotta
N/A26.38 millionN/AN/A
MultiPlan Co. stock logo
MPLN
MultiPlan
17016.17 million14.88 millionOptionable
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
2,100128.66 million126.79 millionOptionable

Recent News About These Companies

Piper Sandler Keeps Their Buy Rating on NeoGenomics (NEO)
NeoGenomics price target lowered to $12 from $16 at BofA
NeoGenomics Completes Acquisition of Pathline

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Donnelley Financial Solutions stock logo

Donnelley Financial Solutions NYSE:DFIN

$45.07 +0.27 (+0.60%)
Closing price 03:59 PM Eastern
Extended Trading
$44.97 -0.10 (-0.22%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Donnelley Financial Solutions, Inc. provides innovative software and technology-enabled financial regulatory and compliance solutions in the United States, Asia, Europe, Canada, and internationally. It operates through four segments: Capital Markets Software Solutions (CM-SS); Capital Markets Compliance and Communications Management (CM-CCM); Investment Companies Software Solutions (IC-SS); and Investment Companies Compliance and Communications Management (IC-CCM). The CM-SS segment provides Venue and ActiveDisclosure solutions to public and private companies to manage public and private transactional and compliance processes; collaborate; and tag, validate, and file SEC documents. The CM-CCM segment offers tech-enabled services and print and distribution solutions to public and private companies for deal solutions and SEC compliance requirements. The IC-SS segment provides clients with the Arc Suite platform that contains a comprehensive suite of cloud-based solutions, including ArcDigital, ArcReporting, ArcPro, and ArcRegulatory, as well as services that enable storage and management of compliance and regulatory information in a self-service and central repository for accessing, assembling, editing, translating, rendering, and submitting documents to regulators and investors. The IC-CCM segment offers tech-enabled solutions for creating, filing and distributing regulatory communications, and solutions for investor communications, as well as XBRL and iXBRL-formatted filings pursuant for Investment Company Act through the SEC's EDGAR system. This segment also provides turnkey proxy services, including discovery, planning and implementation, print and mail management, solicitation, tabulation services, stockholder meeting review, and expert support. Donnelley Financial Solutions, Inc. was founded in 1983 and is headquartered in Chicago, Illinois.

Ibotta stock logo

Ibotta NYSE:IBTA

$48.36 -0.11 (-0.23%)
As of 03:59 PM Eastern

Ibotta’s mission is to Make Every Purchase Rewarding. Our technology allows CPG brands to deliver digital promotions to over 200 million consumers through a single, convenient network called the Ibotta Performance Network (IPN). We are pioneers in success-based marketing: we only get paid when our client’s promotion results in a sale, not when a consumer merely views or clicks on the promotion. We have built the largest digital item-level promotions network in the United States by forming strategic relationships with major retailers such as Walmart Inc. (Walmart) and Dollar General Corporation (Dollar General), which use our digital offers to power their loyalty programs on a white-label basis. Through the IPN, our clients can also reach millions more consumers on our widely used rewards app digital properties, which include the Ibotta-branded cash back mobile app, website, and browser extension (collectively, Ibotta D2C). We work directly with over 850 different clients, representing over 2,400 different CPG brands to source exclusive offers as of December 31, 2023. Most of our offers cover products in non-discretionary categories, such as grocery, but we also work with general merchandise manufacturers in categories such as toys, clothing, beauty, electronics, pet, home goods, and sporting goods. Over time, our clients have generally ramped up their spend with us, and they rarely drop off our network. In fact, of our top 100 clients, 96% were retained from 2022 to 2023. Our technology platform uses an Artificial Intelligence (AI)-enabled offer engine that is designed to match and distribute the right offer to the right consumer at the right time. This is possible because we receive a large volume of item-level purchase data through our secure point of sale (POS) integrations with 85 different retailers as of December 31, 2023. Using this data, we form a profile of each consumer based on what they have bought in the past and how they have responded to various price promotions. From there, we build recommenders that are driven by machine learning and designed to create personalized savings experiences for each consumer. The more data we accumulate, the smarter our recommenders become. Whatever our clients’ specific objectives may be – such as encouraging brand switching, shortening purchase cycles, incentivizing consumers to stock up, or promoting around key seasonal events – our platform helps them design a promotional campaign to accomplish their goals. Ibotta’s technology tracks which offers are selected by consumers, matches offers to the products that have been purchased, logs redemptions, handles the flow of funds, and takes care of all downstream billing and logistics. We perform the function of “air traffic control,” meaning our network enables offers to be matched, distributed, and redeemed across multiple large third-party publishers in a coordinated fashion. This minimizes the risks that offer budgets are exceeded and that consumers redeem the same offer several times for a single purchase (i.e., offer stacking). Our client tools allow CPG brands to set up campaigns, monitor redemption and budget levels, and analyze overall campaign performance – all in a single, convenient interface. We deliver success-based digital promotions at-scale because we manage a growing, open network of third-party publishers that host our offers. Retailers are among our most important publishers because their apps and websites are frequently visited by consumers with high purchase intent. A retailer may ingest digital offers from Ibotta’s Application Programming Interface (API) and present them to its consumers as part of its own branded loyalty program. We call these partners “retailer publishers.” We believe retailer publishers choose to work with Ibotta because we are a trusted partner that can provide a large universe of exclusive offers coupled with a set of plug and play capabilities that would be difficult for them to create and scale on their own. For example, Ibotta and Walmart entered into a multi-year strategic relationship that makes Ibotta the exclusive provider of digital item-level rebate offer content for Walmart U.S., across all product categories, for online and offline shopping. Consumers redeem our offers on Walmart properties without ever creating an Ibotta account. Instead, they can select manufacturer offers from the Walmart website or app, buy the featured items in-store or online, and instantly earn Walmart Cash which can be applied to future purchases in a Walmart store or on Walmart.com. All CPG brands wishing to run digital item-level rebates on Walmart’s website can only do so through the IPN. Ibotta also partners with several other leading retailer publishers. For example, Ibotta partners with Family Dollar, a subsidiary of Dollar Tree, Inc. We also work indirectly to publish offers on certain retailer properties, including Kroger (powering Kroger Cash) and Shell (powering Shell Fuel Rewards). In addition to providing digital offers for retailers, Ibotta also makes the same offers available on its own digital properties, which include Ibotta D2C. Since 2012, over 50 million Americans have registered for our free app. Ibotta D2C reaches a highly engaged audience of savings-conscious consumers who want a single digital starting point where they can find cash back offers across a variety of retailers. Many of these consumers decide where to shop based on the availability of deals in different retailers. Once the IPN launched, Ibotta D2C became a publisher on the IPN, meaning it is now one of many nodes through which our digital offers are delivered to the end consumer. In the future, we believe the IPN may be extended to other publishers across a variety of new verticals. For example, new publishers could include delivery services, banks, or other apps and websites that want to give their consumers access to offers on popular everyday items without having to source those offers from thousands of different CPG brands or secure item-level data from multiple integrated retailers where the offers can be redeemed. We believe Ibotta is well positioned to capitalize on a large and growing market opportunity. U.S. consumers spent approximately $1.2 trillion dollars in the grocery sector in 2023. CPG brands compete fiercely to influence consumer spending habits, spending approximately $200 billion on marketing annually in the United States. In fact, no other industry spends more on marketing, as a percentage of overall budgets, than CPG. Most of our revenue is redemption revenue which is generated from redemptions of offers across the IPN. A significant portion of that redemption revenue arises from offer redemptions on third-party publishers. We also generate revenue by selling ad products on our Ibotta D2C properties. Specifically, we allow CPG brands and retailers to enhance awareness of their offers by buying display ads, in-app videos, or email marketing campaigns. We also charge partners a licensing fee to leverage our aggregated data in ways that help them better understand their target consumers and improve their promotional activities. Finally, on Ibotta’s D2C properties, we also allow thousands of online retailers to advertise and present consumers with their own sitewide cash back offers. These clients benefit from the incremental sales generated by Ibotta’s savings-conscious audience. Our revenue growth significantly accelerated with the addition of new publishers to the IPN. Most recently, the rollout of our offers on the digital property of Walmart has attracted larger audiences, and in turn, resulted in greater spend by CPG brands and a greater number of redeemed offers. These developments have increased our scale, growth and profitability. • Total revenue grew from $210.7 million in 2022 to $320.0 million in 2023, an increase of 52%; • Redemption revenue grew from $138.7 million (or 66% of total revenue) in 2022 to $243.9 million (or 76% of total revenue) in 2023, an increase of 76%; • Gross profit grew from $164.5 million in 2022 to $276.0 million in 2023, an increase of 68%; • Net income (loss) improved from $(54.9) million in 2022 to $38.1 million in 2023; • Net income (loss) as a percent of revenue improved from (26)% in 2022 to 12% in 2023; and • Adjusted EBITDA margin improved from (13)% in 2022 to 26% in 2023. We were incorporated in 2011 as Zing Enterprises, Inc., a Delaware corporation. In 2012, we changed our name to Ibotta, Inc. Our principal executive office is located at 1801 California Street, Suite 400, Denver, Colorado.

MultiPlan stock logo

MultiPlan NYSE:MPLN

$22.57 +0.35 (+1.58%)
As of 04/24/2025

MultiPlan Corporation, together with its subsidiaries, provides data analytics and technology-enabled cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers analytics-based services that reduce medical costs, through data-driven algorithms and insights that detect claims over-charges and negotiate or recommend reimbursement; and network-based services that provide contracted discounts with healthcare providers, as well as outsourced network development and management services. It provides payment and revenue integrity services, such as identifying and removing improper and unnecessary charges paid during the claim, as well as services to identify and help restore and preserve underpaid premium dollars. In addition, the company offers data and decision science services including a suite of solutions that apply modern methods of data science to produce descriptive, predictive, and prescriptive analytics that drive optimized benefit plan design, support decision-making, improve clinical outcomes, and reduce the total cost of care; and business-to-business healthcare payments and other services. It serves national and regional insurance companies, Blue Cross and Blue Shield plans, provider-sponsored and independent health plans, TPAs, self-insured health plans, property and casualty insurers, bill review companies, and other companies involved in the claim adjudication process. MultiPlan Corporation was founded in 1980 and is headquartered in New York, New York.

NeoGenomics stock logo

NeoGenomics NASDAQ:NEO

$10.27 +0.18 (+1.78%)
Closing price 04:00 PM Eastern
Extended Trading
$10.28 +0.01 (+0.05%)
As of 05:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.